EXACT Sciences Research Development Over Time
| EXAS Stock | USD 102.43 0.09 0.09% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out EXACT Sciences Performance and EXACT Sciences Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of EXACT Sciences. If investors know EXACT will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about EXACT Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.35) | Revenue Per Share | Quarterly Revenue Growth 0.201 | Return On Assets | Return On Equity |
The market value of EXACT Sciences is measured differently than its book value, which is the value of EXACT that is recorded on the company's balance sheet. Investors also form their own opinion of EXACT Sciences' value that differs from its market value or its book value, called intrinsic value, which is EXACT Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because EXACT Sciences' market value can be influenced by many factors that don't directly affect EXACT Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between EXACT Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if EXACT Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, EXACT Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Research Development Analysis
Compare EXACT Sciences and related stocks such as Guardant Health, ICON PLC, and Viatris Research Development Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GH | 10.9 M | 10.9 M | 10.9 M | 10.9 M | 10.9 M | 10.9 M | 10.9 M | 25.6 M | 50.7 M | 86.3 M | 149.9 M | 263.2 M | 373.8 M | 367.2 M | 347.8 M | 399.9 M | 204.8 M |
| VTRS | 42.6 M | 294.7 M | 401.3 M | 507.8 M | 581.8 M | 671.9 M | 826.8 M | 783.3 M | 704.5 M | 639.9 M | 512.6 M | 681 M | 662.2 M | 805.2 M | 808.7 M | 930 M | 976.5 M |
| BBIO | 30.6 M | 30.6 M | 30.6 M | 30.6 M | 30.6 M | 30.6 M | 30.6 M | 30.6 M | 140.1 M | 209.9 M | 337 M | 451 M | 399.5 M | 455.7 M | 506.5 M | 582.4 M | 347.9 M |
| SMMT | 504.6 K | 4.8 M | 7.5 M | 6.6 M | 15.6 M | 23.9 M | 23.7 M | 41 M | 51.4 M | 39.2 M | 53.3 M | 85.4 M | 52 M | 59.5 M | 150.8 M | 173.4 M | 182.1 M |
| RVTY | 44.9 M | 115.1 M | 132.1 M | 132.5 M | 120.5 M | 112 M | 123.8 M | 139.2 M | 186.1 M | 189.3 M | 205.4 M | 200.3 M | 221.6 M | 216.6 M | 196.8 M | 226.4 M | 136 M |
| ROIV | 513 M | 513 M | 513 M | 513 M | 513 M | 513 M | 513 M | 513 M | 513 M | 263.2 M | 236.6 M | 483 M | 525.2 M | 439.9 M | 550.4 M | 633 M | 473.2 M |
| RVMD | 26.6 M | 26.6 M | 26.6 M | 26.6 M | 26.6 M | 26.6 M | 26.6 M | 26.6 M | 51.1 M | 91.8 M | 132.3 M | 186.9 M | 253.1 M | 423.1 M | 592.2 M | 681.1 M | 715.1 M |
| DOCS | 27.5 M | 27.5 M | 27.5 M | 27.5 M | 27.5 M | 27.5 M | 27.5 M | 27.5 M | 27.5 M | 32.4 M | 43.9 M | 62.4 M | 80.2 M | 82 M | 93 M | 107 M | 66.2 M |
| QGEN | 4.4 M | 130.6 M | 122.5 M | 146.1 M | 163.6 M | 147.2 M | 176.1 M | 154.1 M | 161.9 M | 157.4 M | 149.1 M | 190 M | 189.9 M | 198.5 M | 193.5 M | 222.5 M | 233.6 M |
EXACT Sciences and related stocks such as Guardant Health, ICON PLC, and Viatris Research Development description
My Equities
My Current Equities and Potential Positions
| EXACT Sciences | EXAS |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 5505 Endeavor Lane, |
| Exchange | NASDAQ Exchange |
USD 102.43
Additional Tools for EXACT Stock Analysis
When running EXACT Sciences' price analysis, check to measure EXACT Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy EXACT Sciences is operating at the current time. Most of EXACT Sciences' value examination focuses on studying past and present price action to predict the probability of EXACT Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move EXACT Sciences' price. Additionally, you may evaluate how the addition of EXACT Sciences to your portfolios can decrease your overall portfolio volatility.